UNLABELLED: Several methods have been and are in use for assessing the in vitro sensitivity and resistance of an individual woman's tumor cells. We report the predictive accuracy of an optimized chemoresponsiveness test. PATIENTS AND METHODS: In a retrospective chart review of 18 women with late stage, papillary serous ovarian cancer undergoing 21 episodes of chemotherapy, we assessed the correlation between the results of this test, the ChemoFx Assays, and clinical response. RESULTS: The positive predictive value of the ChemoFx Assay was 63.6% and the negative predictive value was 100%. Survival curves among women with good vs. poor response on the chemoresponse test showed an early, albeit non-significant survival advantage among women whose tumors tested sensitive to the chemotherapeutic regimens used. CONCLUSION: This study suggests that optimized chemoresponse assays may be beneficial in selecting specific chemotherapy regimens for women with ovarian cancer.
UNLABELLED: Several methods have been and are in use for assessing the in vitro sensitivity and resistance of an individual woman's tumor cells. We report the predictive accuracy of an optimized chemoresponsiveness test. PATIENTS AND METHODS: In a retrospective chart review of 18 women with late stage, papillary serous ovarian cancer undergoing 21 episodes of chemotherapy, we assessed the correlation between the results of this test, the ChemoFx Assays, and clinical response. RESULTS: The positive predictive value of the ChemoFx Assay was 63.6% and the negative predictive value was 100%. Survival curves among women with good vs. poor response on the chemoresponse test showed an early, albeit non-significant survival advantage among women whose tumors tested sensitive to the chemotherapeutic regimens used. CONCLUSION: This study suggests that optimized chemoresponse assays may be beneficial in selecting specific chemotherapy regimens for women with ovarian cancer.
Authors: Candace M Howard; Jagan Valluri; Anthony Alberico; Terrence Julien; Rida Mazagri; Robert Marsh; Hoyt Alastair; Antonio Cortese; Michael Griswold; Wanmei Wang; Krista Denning; Linda Brown; Pier Paolo Claudio Journal: Transl Oncol Date: 2017-02-12 Impact factor: 4.243
Authors: Robert L Ochs; Jeffrey Fensterer; N Paul Ohori; Alan Wells; Michael Gabrin; Lisa D George; Paul Kornblith Journal: In Vitro Cell Dev Biol Anim Date: 2003 Jan-Feb Impact factor: 2.416
Authors: Sarah E Mathis; Anthony Alberico; Rounak Nande; Walter Neto; Logan Lawrence; Danielle R McCallister; James Denvir; Gerrit A Kimmey; Mark Mogul; Gerard Oakley; Krista L Denning; Thomas Dougherty; Jagan V Valluri; Pier Paolo Claudio Journal: PLoS One Date: 2014-08-21 Impact factor: 3.240
Authors: E C Grendys; J V Fiorica; J W Orr; R Holloway; D Wang; C Tian; J K Chan; T J Herzog Journal: Clin Transl Oncol Date: 2014-07-02 Impact factor: 3.405
Authors: Candace M Howard; Stephen Bush; Nadim Bou Zgheib; Seth T Lirette; Antonio Cortese; Antonio Mollo; Jagan Valluri; Pier Paolo Claudio Journal: HSOA J Stem Cells Res Dev Ther Date: 2021-09-09